ImmunityBio Appoints Dr. Linda Maxwell and CEO Richard Adcock to Board of Directors

$IBRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $IBRX alert in real time by email

CULVER CITY, Calif.--()--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the appointment of health innovation expert and executive Linda Maxwell, M.D., MBA, as an independent member of the company’s board of directors. The company also appointed CEO Richard Adcock to the board; he was named CEO of NantKwest in October and remains the CEO of the company after the merger of NantKwest with ImmunityBio in March. Both appointments are effective March 29, 2021.

The nine-member ImmunityBio board is led by Founder and Executive Chairman Patrick Soon-Shiong, M.D. The board includes two other recently appointed outside members, former CIA director John Brennan and retired U.S. Army General Wesley Clark, along with current board members Michael Blaszyk, Cheryl Cohen, Christobel Selecky, and Barry Simon, M.D.

“Linda’s background as a physician and surgeon combined with her extensive global healthcare industry and business experience will enable us to build on ImmunityBio’s strong foundation and help us take the company to the next level,” said Soon-Shiong. “As a company working to bring novel therapeutic approaches to treating cancer and other serious conditions, we will benefit greatly from Linda’s insights on innovation.”

The company also announced that two current directors—Fred Driscoll and John D. Thomas—will conclude their service on the board effective with the new appointments.

“We are grateful to Fred and John for their many years of service and the value they brought to our shareholders and employees,” said Soon-Shiong. “During their tenure, we have expanded our pipeline and grown our portfolio of immunotherapy agents. Their contributions during that time were important to establishing this strong foundation and baseline for the growth we anticipate.”

About Dr. Linda Maxwell

Dr. Maxwell is a medical educator, surgeon, and health technology entrepreneur and innovator. She has guided a wide variety of startup companies through clinical development capitalization and commercialization as Founder and Executive Director of the Biomedical Zone, Canada’s first and only hospital-embedded, physician-led business incubator for emerging health technology companies. Dr. Maxwell also managed a life sciences tech transfer portfolio at the University of Oxford and the UK national Health Service, executing patent strategy, spin-out company formation, and early stage capital raising. She has also served as a healthcare innovation expert in various Canadian federal, provincial, and local government entities, as a member of the Department Audit Committee and the Public Health Agency of Canada, as an advisor to the Canadian Medial Association and the Canadian Space Agency. Dr. Maxwell earned an A.B. with honors from Harvard University, an M.D. from Yale University and an M.B.A. from the University of Oxford. She serves as an independent member of the Board of Directors of United Therapeutics, Inc.

“I’m honored to join the ImmunityBio board at such an important time of growth and opportunity for the company,” she said. “I’m impressed with both the science and the leadership that I believe will take the company on an upward trajectory as it makes innovative contributions to medicine.”

About ImmunityBio

ImmunityBio is a leading, late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term “immunological memory.”

ImmunityBio has a comprehensive immunotherapy pipeline with more than 40 clinical trials (company sponsored or investigator initiated)—of which 25 are at Phase II and III stage of development—across 19 indications in solid and liquid cancers and infectious diseases. Currently 17 first-in human immunotherapy agents are in clinical testing and, to date, over 1,800 patients have been studied with our antibody cytokine fusion proteins, albumin chemo immunomodulators, Adeno and yeast vaccines and our off-the-shelf natural killer cell products. Anktiva™ (ImmunityBio’s lead cytokine infusion protein) is a novel interleukin-15 (IL-15) superagonist complex and has received Breakthrough Therapy and Fast Track Designations from the U.S. Food and Drug Administration (FDA) for BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC).

The company’s platforms are based on the foundation of four separate modalities: Antibody cytokine fusion proteins, synthetic immunomodulators, second-generation human adenovirus (hAd5) and yeast vaccine technologies, and state-of-the-art, off-the-shelf natural killer cells, including autologous and allogenic cytokine-enhanced memory NK cells. ImmunityBio is currently developing a dual construct COVID-19 vaccine candidate using its hAd5 platform.

ImmunityBio is a leading producer of cryopreserved and clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The company has established GMP manufacturing capacity at scale with cutting-edge cell manufacturing expertise and ready-to-scale facilities, as well as extensive and seasoned R&D, clinical trial, and regulatory operations and development teams. For more information, please visit: www.immunitybio.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues”, “could”, “estimates,” “expects,” “intends,” “may,” “plans,” “potential”, “predicts”, “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. These forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio’s management as well as assumptions made by and information currently available to ImmunityBio. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) potential adverse effects or changes to relationships with employees, suppliers or other parties resulting from the completion of the merger of NantKwest and ImmunityBio, Inc., (ii) the outcome of any legal proceedings that may be instituted against the parties and others related to the merger, (iii) unexpected costs, charges or expenses resulting from the merger, (iv) uncertainty of the expected financial performance of the combined company following completion of the merger, including the possibility that the expected synergies and value creation from the merger will not be realized or will not be realized within the expected time period, (v) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs, and the timing and success of any such continued preclinical and clinical development and planned regulatory submissions, (vi) inability to retain and hire key personnel, and (vii) the unknown future impact of the COVID-19 pandemic delay on certain clinical trial milestones and/or ImmunityBio’s operations or operating expenses. More details about these and other risks that may impact ImmunityBio’s business are described under the heading “Risk Factors” in the Company’s Form 8-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 10, 2021 and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC’s website at www.sec.gov. ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.

Get the next $IBRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IBRX

DatePrice TargetRatingAnalyst
3/6/2025$8.00Buy
H.C. Wainwright
1/10/2025$6.00Buy
BTIG Research
5/12/2023$10.00 → $4.00Overweight → Neutral
Piper Sandler
8/3/2022$8.00Buy
Jefferies
More analyst ratings

$IBRX
Press Releases

Fastest customizable press release news feed in the world

See more
  • ImmunityBio to Host Investor Day

    ImmunityBio, Inc. ((IBRX), a leading immunotherapy company, invites current and prospective investors to its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company's business operations and recent R&D advancements. Key timelines for catalysts of product candidates will be presented, along with a discussion of ongoing clinical trials. "ImmunityBio commenced 2025 with notable scientific and business milestones," said Richard Adcock, President and CEO of ImmunityBio. "With a promising future ahead, we are eager to engage with our investors and share the reasons we're optimistic and excited about the company's gro

    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

    U.S. Urology Partners is one of the first providers to offer patients ImmunityBio's recombinant Bacillus Calmette-Guérin (rBCG) The FDA recently authorized ImmunityBio's EAP for rBCG to address U.S. shortages and provide an alternative source of BCG, a critical standard-of-care in bladder cancer Multiple urology centers across the U.S. are in the process of activating their sites to administer rBCG ImmunityBio, Inc. ((IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation's largest independent providers of urology and related specialty services, is one of the first providers to participate in ImmunityBio's Expanded Access Program (EAP) for re

    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

    With a permanent J-code (J9028) awarded in January 2025, ImmunityBio's February 2025 ANKTIVA® unit sales volume grew 97% over unit sales volume in December 2024 ANKTIVA sales momentum continues to trend upward quarter to date 2025, with sales volume in February representing a 67% increase month-over-month from January Sales volume in the 2 months in 2025 to date shows a 69% increase over the sales volume in the 2 months prior (November and December 2024) and already exceeds the total units for all of Q4 2024 For the three-month period ending December 31, 2024 prior to permanent J-code approval, ImmunityBio achieved net product revenue of approximately $7.2 million, surpassing net

    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$IBRX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$IBRX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$IBRX
SEC Filings

See more

$IBRX
Leadership Updates

Live Leadership Updates

See more
  • ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update

    ImmunityBio, Inc. ((IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time. The Annual Meeting will be held in a virtual-only format and there will not be a physical location for the Annual Meeting. Stockholders of record at the close of business on April 17, 2024 are entitled to vote at and participate in the Annual Meeting. Richard Adcock, the Company's Chief Executive Officer and President, will provide a business update after the formal business of the Annual Meeting has ended. All interested parties are welcome to attend the Annual Meeting and listen to the Company update. Non-stockholders can attend the vir

    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Faraday Future Announces Chief Accounting Officer and Interim Chief Financial Officer, and Funding Progress

    - Yun Han named Chief Accounting Officer and Interim Chief Financial Officer - - Initial Funding Expected This Week Under $60 Million Financing Agreement - Faraday Future Intelligent Electric Inc. ("Faraday Future" or the "Company") (NASDAQ:FFIE), a California-based global shared intelligent electric mobility ecosystem company, today announced the appointment of Yun Han as Chief Accounting Officer and Interim Chief Financial Officer, effective October 25, 2022. Ms. Han replaces Becky Roof, who served as interim Chief Financial Officer until October 12, 2022, and is assisting the Company to ensure an orderly transition. This press release features multimedia. View the full release here: htt

    $FFIE
    $IBRX
    $RMO
    Auto Manufacturing
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • ImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives

    Biopharma leaders bring proven market development talents in urology and oncology to bolster company's commercialization plan and long-term growth plans Helen Luu, former CEO of Cell BT, is named ImmunityBio's first Chief Commercial Officer and brings a strong background in product commercialization in the urology market, business development, sales growth, and oncology market expansion. Sigrid Schreiner joins as Senior Vice President of Global Market Access, adding decades of market access experience to the leadership team, including the market launch of chemotherapy Abraxane®. ImmunityBio, Inc. (NASDAQ:IBRX), a clinical-stage immunotherapy company, today announced two key executive

    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$IBRX
Financials

Live finance-specific insights

See more
  • ImmunityBio Reports Third-Quarter 2024 Financial Results

    ImmunityBio, Inc. ((IBRX) today announced its financial results for the third-quarter ended September 30, 2024. ANKTIVA® received a J-code (HCPCS Level II Code) in October 2024, effective January 1, 2025. ANKTIVA (FDA-approved and commercially available in the U.S. since May 2024) is now widely accessible to patients through commercial and government insurance programs (VA, DoD, Medicare). ImmunityBio has secured coverage for over 200 million medical lives through medical reimbursement policies. ImmunityBio achieved a net product revenue of approximately $6.0 million during the three months ended September 30, 2024, surpassing net product revenue of $1.0 million in the prior quarte

    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association

    Dr. Sam S. Chang, Professor of Urology at Vanderbilt Cancer Program, to host the program "A Deep Dive with Patrick Soon-Shiong: Next-Generation Immunotherapy for NMBIC" Discussion about the basis for ANKTIVA's Breakthrough Therapy designation and the novel mechanism of how the IL-15 superagonist achieves durable complete responses in BCG unresponsive NMIBC The Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio, Inc. ((IBRX), a next-generation immunotherapy company, will discuss the implications of the recent FDA approval of ANKTIVA® (nogapendekin alfa inbakicept-pmln) for use in combination with bacillus Calmette-Guerin (BCG) for non-muscle invasive bl

    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

    QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy Positive results seen in both PD-L1 negative and PD-L1 positive participants with NSCLC Data reaffirms the mechanism of action of ANKTIVA as an immune cell enhancer that activates natural killer (NK) cells and memory T cells to rescue checkpoint inhibitor (pembrolizumab, nivolumab, atezolizumab) failures across multiple tumor types Meeting scheduled with FDA in June to discuss path to registration filing of ANKTIVA plus che

    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$IBRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more